Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
miR-9 is a tumor suppressor in pediatric AML with t(8;21).
Emmrich S, Katsman-Kuipers JE, Henke K, Khatib ME, Jammal R, Engeland F, Dasci F, Zwaan CM, den Boer ML, Verboon L, Stary J, Baruchel A, de Haas V, Danen-van Oorschot AA, Fornerod M, Pieters R, Reinhardt D, Klusmann JH, van den Heuvel-Eibrink MM. Emmrich S, et al. Among authors: klusmann jh. Leukemia. 2014 May;28(5):1022-32. doi: 10.1038/leu.2013.357. Epub 2013 Nov 25. Leukemia. 2014. PMID: 24270738
Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
Jarisch A, Salzmann-Manrique E, Soerensen J, Sach G, Rettinger E, Willasch A, Bakhtiar S, Klarmann D, Bräuninger S, Moser L, Fekadu J, Hutter M, Klingebiel T, Klusmann JH, Bader P, Bonig H. Jarisch A, et al. Among authors: klusmann jh. Br J Haematol. 2023 Jun;201(6):1159-1168. doi: 10.1111/bjh.18761. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949601
Double trouble: IRAK1/4 inhibitors in AML/MDS.
Uckelmann HJ, Klusmann JH. Uckelmann HJ, et al. Among authors: klusmann jh. Blood. 2023 Sep 14;142(11):945-946. doi: 10.1182/blood.2023020812. Blood. 2023. PMID: 37707874 No abstract available.
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.
Raghuram N, Hasegawa D, Nakashima K, Rahman S, Antoniou E, Skajaa T, Merli P, Verma A, Rabin KR, Aftandilian C, Kotecha RS, Cheuk D, Jahnukainen K, Kolenova A, Balwierz W, Norton A, O'Brien M, Cellot S, Chopek A, Arad-Cohen N, Goemans B, Rojas-Vasquez M, Ariffin H, Bartram J, Kolb EA, Locatelli F, Klusmann JH, Hasle H, McGuire B, Hasnain A, Sung L, Hitzler J. Raghuram N, et al. Among authors: klusmann jh. Blood Adv. 2023 Nov 14;7(21):6532-6539. doi: 10.1182/bloodadvances.2022009381. Blood Adv. 2023. PMID: 36735769 Free PMC article.
Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U, Reinhardt D. Ehlers S, et al. Among authors: klusmann jh. J Clin Oncol. 2010 May 20;28(15):2591-7. doi: 10.1200/JCO.2009.25.9010. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406937 Clinical Trial.
91 results